Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Hunter, Joshua H ^a   Gujjar, Ramesh ^a   Pang, Cullen K T ^a   Rathod, Pradipsinh K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; DNA; FLOXURIDINE PHOSPHATE; FOLIC ACID ANTAGONIST; GENE PRODUCT; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE A; THYMIDYLATE SYNTHASE X; ENZYME INHIBITOR; ISOENZYME; LIGAND; PRIMER DNA;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME SYNTHESIS; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGAND BINDING; MACROMOLECULE; MOLECULAR CLONING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; DRUG ANTAGONISM; ENZYME SPECIFICITY; ENZYMOLOGY; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; NUCLEOTIDE SEQUENCE;

MYCOBACTERIUM TUBERCULOSIS;

BASE SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA PRIMERS; ENZYME INHIBITORS; ISOENZYMES; KINETICS; LIGANDS; MYCOBACTERIUM TUBERCULOSIS; SUBSTRATE SPECIFICITY; THYMIDYLATE SYNTHASE;

EID: 48249126476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002237     Document Type: Article

References (46)

1. Keeler E, Perkins MD, Small P, Hanson C, Reed S, et al. (2006) Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 444 Suppl 1: 49-57.
2. Shah NS, Wright A, Bai GH, Barrera I, Boulahbal F, et al. (2007) Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13: 380-387.
3. du Toit LC, Pillay V, Danckwerts MP (2006) Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 7: 118
4. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheirn A, et al. (2007) Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 4: e238.
5. Harper C (2007) Tuberculosis, a neglected opportunity? Nat Med 13: 309-312.
6. Hardy LW, Finer-Moore JS, Montfort WR, Jones MO, Santi DV, et al. (1987) Atomic structure of thymidylate synthase: target for rational drug design. Science 235: 448-455.
7. Carreras CW, Santi DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 61: 721-762.
8. Ingraham HA, Dickey L, Goulian M (1986) DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate. Biochemistry 25: 3225-3230.
9. Curtin NJ, Harris AL, Aherne GW (1991) Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 51: 2346-2352.
10. Touroutoglou N, Pazdur R (1996) Thymidylate synthase inhibitors. Clin Cancer Res 2: 227-243.
11. Stout TJ, Tondi D, Rinaldi M, Barlocco D, Pecorari P, et al. (1999) Structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry 38: 1607-1617.
12. Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, et al. (2004) The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol 53: 275-282.
13. Myllykallio H, Lipowski G, Leduc D, Filee J, Forterre P, et al. (2002) An alternative flavin-dependent mechanism for thymidylate synthesis. Science 297: 105-107.
14. Jiang L, Lee PC, White J, Rathod PK (2000) Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob Agents Chemother 44: 1047-1050.
15. Rathod PK, Leffers NP, Young RD (1992) Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrob Agents Chemother 36: 704-711.
16. Sampathkumar P, Turley S, Ulmer JE, Rhie HG, Sibley CH, et al. (2005) Structure of the Mycobacterium tuberculosis flavin dependent thymidylate synthase (MtbThyX) at 2.0A resolution. J Mol Biol 352: 1091-1104.
17. Kuhn P, Lesley SA, Mathews, II, Canaves JM, Brinen LS, et al. (2002) Crystal structure of thyl, a thymidylate synthase complementing protein from Thermotoga maritima at 2.25 A resolution. Proteins 49: 142-145.
18. Ulmer JE, Boum Y, Thouvenel CD, Myllykallio H, Sibley CH (2008) Functional analysis of the Mycobacterium tuberculosis FAD-dependent thymidylate synthase, ThyX, reveals new amino acid residues contributing to an extended ThyX motif. J Bacteriol 190: 2056-2064.
19. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
20. Sassetti CM, Rubin EJ (2003) Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A 100: 12989-12994.
21. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, et al. (1991) Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A 88: 8977-8981.
22. Zhang K, Rathod PK (2002) Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science 296: 545-547.
23. Chu E, Voeller D, Koeller DM, Drake JC, Takimoto CH, et al. (1993) Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci U S A 90: 517-521.
24. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31: 3497-3500.
25. Dolnick BJ, Cheng Y (1977) Human thymidylate synthetase derived from blast cells of patients with acture myclocytic leukemia. Purification and chracterization. J Biol Chem 252: 7697-7703.
26. Davisson VJ, Sirawaraporn W, Santi DV (1989) Expression of human thymidylate synthase in Escherichia coli. J Biol Chem 264: 9145-9148.
27. Graziani S, Xia Y, Gumon JR, Van Etten JL, Leduc D, et al. (2004) Functional analysis of FAD-dependent thymidylate synthase ThyX from Paramecium bursaria Chlorella virus-1. J Biol Chem 279: 54340-54347.
28. Leduc D, Graziani S, Lipowski G, Marchand C, Le Marechal P, et al. (2004) Functional evidence for active site location of tetrameric thymidylatc synthase X at the interphase of three monomers. Proc Natl Acad Sci U S A 101: 7252-7257.
29. Graziani S, Bernauer J, Skouloubris S, Graille M, Zhou CZ, et al. (2006) Catalytic mechanism and structure of viral flavin-dependent thymidylate synthase ThyX. J Biol Chem 281: 24048-24057.
30. Griffin J, Roshick C, Iliffe-Lec E, McClarty G (2005) Catalytic mechanism of Chlamydia trachomatis flavin-dependent thymidylate synthase. J Biol Chem 280: 5456-5467.
31. Agrawal N, Lesley SA, Kuhn P, Kohen A (2001) Mechanistic studies of a flavin-dependent thymidylate synthase. Biochemistry 43: 10295-10301.
32. Gomez ZM, Rathod PK (1990) Antimalarial activity of a combination of 5-fluoroorotate and uridine in mice. Antimicrob Agents Chemother 34: 1371-1375.
33. Rathod PK, Khatri A, Hubbert T, Milhous WK (1989) Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 33: 1090-1094.
34. Baldwin J, Farajallah AM, Malmquist NA, Rathod PK, Phillips MA (2002) Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem 277: 41827-41834.
35. Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, et al. (2005) High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 280: 21847-21853.
36. Phillips MA, Gujjar R, Malmquist NA, White J, El Mazouni F, et al. (2008) Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite, Plasmodium falciparum. Journal of Medicinal Chemistry: In press.
37. Ackermann WW, Potter VR (1919) Enzyme inhibition in relation to chemotherapy. Proc Soc Exp Biol Med 72: 1-9.
38. Cha S, Agarwal RP, Parks RE Jr (1975) Tight-binding inhibitors-II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine dcaminase by coformycin. Biochem Pharmacol 24: 2187-2197.
39. Cha S (1975) Tight-binding inhibitors-I. Kinetic behavior. Biochem Pharmacol 24: 2177-2185.
40. Hekmat-Nejad M, Rathod PK (1996) Kinetics of Plasmodium falciparum thymidylate synthase: interactions with high-affinity metabolites of 5-fluoroorotate and D 1694. Antimicrob Agents Chemother 40: 1628-1632.
41. Gattis SG, Palfey BA (2005) Direct observation of the participation of flavin in product formation by thyX-encoded thymidylate synthase. J Am Chem Soc 127: 832-833.
42. Sampathkumar P, Turley S, Sibley CH, Hol WG (2006) NADP+ expels both the co-factor and a substrate analog from the Mycobacterium tuberculosis ThyX active site: opportunities for anti-bacterial drug design. J Mol Biol 360: 1-6.
43. Van Triest B, Pinedo HM, Giaccone G, Peters GJ (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11: 385-391.
44. Pendergast W, Dickerson SH, Dev IK, Ferone R, Duch DS, et al. (1994) Benzo[f]quinazoline inhibitors of thymidylate synthase: methyleneamino-linked aroylglutamate derivatives. J Med Chem 37: 838-844.
45. Whitaker JR (1963) Determination of Molecular Weights of Proteins by Gel Filtration of Sephadex. Anal Chem 35: 1950-1953.
46. Dev IK, Dallas WS, Ferone R, Hanlon M, McKee DD, et al. (1994) Mode of binding of folate analogs to thymidylate synthase. Evidence for two asymmetric but interactive substrate binding sites. J Biol Chem 269: 1873-1882.